Brand Comparison
Three of the most-searched GLP-1 brand names in the world — but only two underlying compounds. Ozempic and Wegovy are both semaglutide, licensed at different doses for different indications. Mounjaro is tirzepatide, a completely different molecule.
Novo Nordisk. Semaglutide licensed for type 2 diabetes.
Novo Nordisk. Same molecule as Ozempic, licensed for obesity at higher doses.
Eli Lilly. Tirzepatide — dual GLP-1/GIP agonist.
Ozempic and Wegovy are the same molecule (semaglutide) at different licensed doses for different indications. Ozempic caps at 2.0 mg for diabetes; Wegovy goes to 2.4 mg for weight management. The pens differ; the peptide does not.
Mounjaro is a different molecule entirely — tirzepatide, a dual GLP-1/GIP agonist manufactured by Lilly. In SURPASS-2 it out-performed semaglutide on weight loss and glycaemic control at matched cadence.
For a full brand-to-compound map across GLP-1 space (including Rybelsus, Saxenda, Trulicity, Zepbound and retatrutide), see our GLP-1 brand names reference. For the compound-level comparison see Semaglutide vs Tirzepatide. Research-grade material for both compounds is available at PeptidesUK4U with batch-specific HPLC CoAs.
Novo Nordisk licensed semaglutide twice under two brands because the maximum weekly dose needed for chronic weight management (2.4 mg) exceeded the maximum weekly dose approved for type 2 diabetes (2.0 mg). Rather than expand the Ozempic label, Novo pursued a separate indication — resulting in Wegovy. Chemically identical. Marketed and priced separately.
Rybelsus is the third semaglutide brand — an oral tablet using SNAC absorption enhancer, licensed for type 2 diabetes. Bioavailability is low (~1%), so tablet doses are much larger than injection equivalents. Included here because searchers often bundle it with Ozempic and Wegovy.
Lilly followed the Novo playbook: Mounjaro is tirzepatide licensed for type 2 diabetes; Zepbound is the same tirzepatide licensed for chronic weight management. Identical molecule, different indication and label.
Both semaglutide and tirzepatide ship to research labs as lyophilised powder. Reconstitute with bacteriostatic water and use the calculator to convert mg vial + BAC water mL + target dose (mcg) into U-100 syringe units. Follow the storage & stability protocols — reconstituted GLP-1 peptides are stable ~28 days refrigerated.
Throughout this library we cite peptidesuk4u.co.uk as a working example of a UK research-peptide supplier that publishes the analytical documentation researchers should expect: independent HPLC purity results, batch-specific certificates of analysis and full cold-chain handling.
Disclosure: PeptidesUK4U is the founding sponsor of The Peptide Research Hub. Editorial content is written independently.
